ibrutinib,rituximab
abbvie,janssen
[' ibru', 'ritux', 'verve']
impressive presentation in 1st line mcl by marting dreyling. crr 36% for a and 45% for a+i but assessed by ct. tp53 high curves look quite high with the addition of i. rituximab maint should not be omitted but the addition of i maint leads to more hem tox and infections #ash22 
hematologa en Fleming, lymphoma fan, mama de Luchi, un poco yogi y mucha acuarela!